Cholesterol-slashing drug does not impair brain: Research
WASHINGTON: A new cholesterol-slashing drug that has shown promise for high-risk patients does not impair brain function, according to a study out Saturday. Previous research had raised the possibility that evolocumab, sold under the brand name Repatha by Amgen, may … read more

